icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 19, -23 2022
Washington DC

Back grey_arrow_rt.gif
 
 
 
Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine:
Efficacy and Safety Outcomes Through Week 96 by Race

 
 
  IDWeek 2022 Oct 19-22
 
Parul Patel1, Emilie R. Elliot2, Ronald D'Amico1, Louise Garside3, Conor Smith4, Jeremy Roberts5, Sri Byrapuneni6, Joseph W. Polli1, Moti Ramgopal7, Princy Kumar8, Olayemi Osiyemi9, Bryan Baugh10, Jean van Wyk2
 
1ViiV Healthcare, Research Triangle Park, NC, United States; 2ViiV Healthcare, Brentford, United Kingdom;
3PHASTAR, Macclesfield, United Kingdom; 4Parexel International, Sheffield, United Kingdom; 5GSK, Mississauga, ON, Canada;
6Parexel International, Research Triangle Park, NC, United States; 7Midway Immunology and Research Center, Fort Pierce, FL, United States; 8Georgetown University Medical Center, Washington, DC, United States; 9Triple O Research Institute PA, West Palm Beach, FL, United States;
10Janssen Pharmaceuticals, Research & Development, Titusville, NJ, United States

1024221

1024222

1024223

1024224

1024225

1024226

1024227